151 related articles for article (PubMed ID: 36255265)
1. Fusicoccin-A Targets Cancerous Inhibitor of Protein Phosphatase 2A by Stabilizing a C-Terminal Interaction with 14-3-3.
Brink HJ; van Senten JR; De Vries-van Leeuwen IJ; da Costa Pereira D; Piersma SR; Jimenez CR; Centorrino F; Ottmann C; Siderius M; Smit MJ; de Boer AH
ACS Chem Biol; 2022 Nov; 17(11):2972-2978. PubMed ID: 36255265
[TBL] [Abstract][Full Text] [Related]
2. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
3. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
5. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
Wang J; Okkeri J; Pavic K; Wang Z; Kauko O; Halonen T; Sarek G; Ojala PM; Rao Z; Xu W; Westermarck J
EMBO Rep; 2017 Mar; 18(3):437-450. PubMed ID: 28174209
[TBL] [Abstract][Full Text] [Related]
6. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.
Puustinen P; Rytter A; Mortensen M; Kohonen P; Moreira JM; Jäättelä M
J Cell Biol; 2014 Mar; 204(5):713-27. PubMed ID: 24590173
[TBL] [Abstract][Full Text] [Related]
7. Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Nath S; Ohlmeyer M; Salathe MA; Poon J; Baumlin N; Foronjy RF; Geraghty P
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):695-705. PubMed ID: 30011381
[TBL] [Abstract][Full Text] [Related]
8. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
Jeong AL; Lee S; Park JS; Han S; Jang CY; Lim JS; Lee MS; Yang Y
J Biol Chem; 2014 Jan; 289(1):28-40. PubMed ID: 24214971
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
De P; Carlson J; Leyland-Jones B; Dey N
Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
[TBL] [Abstract][Full Text] [Related]
10. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
11. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
13. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin I attenuates cognitive impairments and reduces AD-like pathology through CIP2A-PP2A signaling pathway in 3XTg-AD mice.
Zhou Y; Yang D; Chen H; Zheng C; Jiang H; Liu X; Huang X; Ye S; Song S; Jiang N; Zhao Z; Ma S; Ma J; Huang K; Chen C; Fan X; Gong Y; Wang X; Fan J; Liu R; Shentu Y
FASEB J; 2020 Dec; 34(12):16414-16431. PubMed ID: 33070372
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
[TBL] [Abstract][Full Text] [Related]
17. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
18. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Pallai R; Bhaskar A; Sodi V; Rice LM
Transcription; 2012; 3(6):323-35. PubMed ID: 23117818
[TBL] [Abstract][Full Text] [Related]
19. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
[TBL] [Abstract][Full Text] [Related]
20. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
